Research Focused on the Elemental Analysis Market Forecast up to 2023

Some of the key players in this market are Thermo Fisher Scientific, Inc. (U.S.), Agilent Technologies, Inc. (U.S.), AMETEK, Inc. (U.S.), PerkinElmer, Inc. (U.S.), Bruker Corporation (U.S.), Shimadzu Corporation (Japan), Elementar Group (Germany) and Rigaku Corporation (Japan) among others.

Elemental analysis is a process of detection and quantification of elemental compounds, molecular species and elements. This analysis technique is a part of analytical chemistry and can be qualitative and quantitative in nature. Sample types tested for trace elements comprises of aqueous, non-aqueous, organic and non-organic materials. For organic chemists, elemental analysis refers to CHNX analysis, which is used to determine the purity and structure of a compound. In this technique, a sample is burnt in excess of oxygen and thereby collecting combustion products like carbon dioxide, nitric acid and water. The masses of these products are used to determine composition of the sample. Ultra trace analysis and elemental trace analysis detection range from parts per million (ppm), to parts per billion (ppb) and parts per trillion (ppt) levels, using updated techniques and instruments. Some of the major technologies used for elemental analysis include inductively coupled plasma mass spectrometry, inductively coupled plasma optical emission spectrometry, X-ray Fluorescence and X-ray Diffraction among others.

Obtain Report Details @ http://www.transparencymarketresearch.com/elemental-analysis-market.html

Some of the key driving factors for elemental analysis market are increasing concern for food safety, increasing usage of X-ray fluorescence in clinical research and growing R&D funding in life sciences. Moreover, this technology has a wide range of application areas in different segments of industry and thus has a major market worldwide. There are other geographical drivers which are also responsible for the growth of the market. In addition, demand from emerging markets across India and China are expected to create opportunities for elemental analysis market in the future. However, high cost of elemental analyzers and urge for efficient professionals act as major restraints to the growth of the market.

Global elemental analysis market can be broadly classified on the basis of types, technology, applications and geography. By types, the market for elemental analysis is segmented into organic and inorganic. The market is divided by technology into destructive and non-destructive technologies. Moreover, elemental analysis has different application areas including food and beverage testing, life sciences, environment testing and geology among others.

Fill the Form to Gain Deeper Insights on this Market @ http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=5144

Currently North America is dominating the market for elemental analysis in terms of revenue, followed by Europe and Asia-Pacific. The major factor responsible for immense development of elemental analysis market in North America is rapid technological advancement of this technique in various application areas, such as food and beverage, biotechnology, chemical and semiconductor industries among others. However, Asia Pacific is anticipated to grow at a significant rate in the future, primarily due to increasing awareness for elemental analysis in China and India coupled with rising demand from applied markets. Furthermore, strategic expansion by manufacturers in China and use of modern analysis technique in Chinese medicines are likely to develop the market for elemental analysis in Asia Pacific.

Global Outlook for Tissue Engineered Skin Substitutes Forecast to 2023 Illuminated by New Report

Tissue Engineered Skin Substitutes Market: Snapshot

The elderly are highly prone to contracting skin diseases such as various forms of ulcers due to their significantly reduced flow of blood and overall immunity against diseases. The number of geriatrics in all nations has been on the rise owing to multiple factors, and a rise in their number is a direct call to action for all related healthcare organizations, products, and services. This includes the tissue engineered skin substitute providers and makes the above the top driver for its market.

The number of patients suffering from skin diseases and ulcers is also increasing within younger demographics. The CDC, for instance, stated in 2015 that close to 900,000 people are affected by DVT per year. A large number of patients were additionally being diagnosed with venous diseases per year, further boosting the need for tissue engineered skin substitutes.

The market is, however, restrained by over competitiveness between local manufacturers and their globally prominent counterparts. The local manufacturers can offer tissue engineered skin substitutes at a much lower price than global ones, forcing the latter to drop prices and consequently their profit margins. This will affect the market’s rate of research and development in the long run.

These drivers and restraints are expected to converge to result in a CAGR of 17.2% for the global market of tissue engineered skin substitutes between 2015 and 2023. This market is expected to be valued at US$1.24 bn by the end of 2016, and US$3.87 bn by 2023.

Obtain Report Details @ http://www.transparencymarketresearch.com/tissue-engineered-skin-substitute.html

North America Continues to Show Strong Demand for Tissue Engineered Skin Substitutes

The need for tissue engineered skin substitutes in North America has consistently been high over the past few years. It is expected to generate US$1.96 bn in revenue for tissue engineered skin substitute players by 2023. A key reason prompting the use of tissue engineered skin substitutes in North America is the very high prevalence of vascular diseases. The region holds an especially high proportion of the geriatric, diabetic, and obese demographics and thus requires tissue engineered skin substitutes to a higher degree than other major regions.

Europe is another key region for tissue engineered skin substitute players. This region shows a similarly high demand as that shown by North America, although at a smaller revenue cap. The highest demand for tissue engineered skin substitutes at the moment, however, comes from Asia Pacific. The revenue earned by tissue engineered skin substitute providers in this region is expected to progress at a CAGR of 18.3% from 2015 to 2023. Key reasons for the high proliferation of tissue engineered skin substitute players in Asia Pacific is the growing geriatric population in nations such as South Korea and Japan, along with the rapidly increasing investments made by governments into the market.

Fill the Form to Gain Deeper Insights on this Market @ http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=3854

Tissue Engineered Skin Substitutes to Find Increasing Demand in Treatment of Ulcers

Ulcers have consistently been the leading application segment for tissue engineered skin substitutes. By the end of 2023, nearly US$2.1 bn will be generated by tissue engineered skin substitute players through ulcer treatment alone. This segment is also expected to grow at a robust CAGR of 17.5% within 2015 and 2023.

The same applies to other skin disorders that are growing in prevalence across the globe. Most dermatology organizations such as the ADA have made their predictions, all of which point to a growing number of patients with skin disorders. The ADA, for instance, in 2013, released findings of a study that stated at least one in every five U.S. citizens will suffer from a skin disorder in their lifetime. This makes the development of dermatology solutions such as tissue engineered skin substitutes a matter of high concern.

The key manufacturers of tissue engineered skin substitutes include Acelity, Smith & Nephew, Molnlycke, ConVatec, Medtronic, and BSN Medical.

Global EpCAM Antagonists Market Forecast to 2023 with Competitive Landscape Analysis and Key Companies Profile

Global EpCAM Antagonists Market: Overview

Epithelial cell adhesion molecule (EpCAM), is a cell surface protein or antigen, which is considered an highly expressed element in most of the key cancer types, including prostate, breast, colon, lung, gastric, ovarian, and pancreatic cancer. As a result, EpCAM antagonists are considered as well-established as an ideal therapeutic target and market for cancer of epithelial origin. The growing focus of leading players on research and development activities and technological advancements in the healthcare sector are projected to encourage the growth of the global EpCAM antagonists market throughout the forecast period.

The research study offers a detailed analysis of the global EpCAM antagonists market, presenting insights into the important factors that are projected to impact the growth of the overall market in the near future. In addition, the driving factors, restraints, and the promising opportunities in the global EpCAM antagonists market have been highlighted in order to offer a strong understanding of the overall market. The product segmentation, innovations and developments, latest trends, major applications, key regional segments, and the competitive landscape of the global EpCAM antagonists market have been discussed in the research report.

Obtain Report Details @ http://www.transparencymarketresearch.com/epcam-antagonists-market.html

Global EpCAM Antagonists Market: Drivers and Barriers

The tremendously rising prevalence of different types of cancer across the globe is one of the key factors estimated to fuel the growth of the global EpCAM antagonists market throughout the forecast period. In addition, the rising government initiatives and spending on research and development activities for cancer treatment are expected to accelerate the growth of the overall market in the next few years. Furthermore, the constant development in the field of recombinant DNA technology is projected to offer promising opportunities for the key players operating in the global market for EpCAM antagonists.

However, the lack of awareness regarding the availability of advanced therapeutics, especially in developing economies and the high cost of overall cancer treatments are some of the key factors likely to restrict the growth of the global EpCAM antagonists market in the coming few years.

Global EpCAM Antagonists Market: Regional Outlook

The global market for EpCAM antagonists can be classified in terms of geography to offer an in-depth analysis. The key regional segments include Asia Pacific, Europe, North America, and the Rest of the World. Among these, North America is projected to lead the overall market and account for a large share throughout the forecast period. The presence of a large number of leading players operating in this region is one of the major factors estimated to supplement the growth of the EpCAM antagonists market in the next few years.

Furthermore, the rising number of cancer cases in this region is another factor encouraging the growth of the market in the next few years. On the other hand, Asia Pacific is projected to witness significant growth in the coming years.

Fill the Form to Gain Deeper Insights on this Market @ http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=4678

Companies Mentioned in the Research Report

Some of the key players operating in the EpCAM antagonists market across the globe are Johnson and Johnson, Amgen, Inc., Fresenius Biotech, The University of Hong Kong and American Association for Cancer Research, and Trion Pharma GmbH. The increasing number of players entering the global market and focusing on research and development activities are some of the factors estimated to accelerate the growth of the global EpCAM antagonists market throughout the forecast period.

Global Aurora Kinase Inhibitors Market Forecast to 2023 with Competitive Landscape Analysis and Key Companies Profile

Companies mentioned in the research report

Cyclacel Pharmaceuticals, Pfizer, Eli Lilly, GlaxoSmithKline, Millennium Pharmaceuticals, Merck, Bristol Myers Squibb, Celgene, Roche, Sanofi, and Novartis are some leading companies operating in the global market for aurora kinase inhibitors.

Global Aurora Kinase Inhibitors Market: Overview

As the importance of aurora kinases was recognized due to their significance in human biology and cancer therapy, the demand for aurora kinase inhibitors has been surmounting of late. Aurora kinases are a type of enzymes that play a significant role in cell proliferation. In the mitosis process, these enzymes undertake the responsibility of breaking down the genetic material of the parent cells via the control of chromatid segregation.

Based on type of aurora kinase enzymes, A, B, and C can be the key segments of the global market for aurora kinase inhibitors. While aurora A and B lead to tumerogenesis, aurora C is associated with spermatogenesis process. Although they are not associated with a certain type of cancer, some instances of cancer exhibit over-expression of a particular type of aurora kinases. Aurora B was found to be related to thyroid, breast, and colon, whereas aurora A was found to be associated with prostate, pancreatic, ovarian, cervical, lung, breast, and brain.

The report offers key information pertaining to the leading growth drivers, deterrents, and market trends. The key opportunities proffered by the different regional segments have been analyzed in detail, alongside relevant market data, charts, and figures. Efficient analytic tools such as the Porter’s Five Force analysis and SWOT analysis have been adopted by the study to produce accurate evaluations. The major players transacting in the global market for aurora kinase inhibitors are also assessed with regards to their market shares, product portfolios, and business strategies.

Obtain Report Details @ http://www.transparencymarketresearch.com/aurora-kinase-inhibitors-market.html

Global Aurora Kinase Inhibitors Market: Trends & Opportunities/Drivers and Restraints

The rising incidence of cancer on a worldwide scale has been fuelling the demand for aurora kinase inhibitors recently. Cancer has been found to be one of the foremost factors increasing mortality rates over the globe. According to the World Health Organization (WHO), by the end of 2025 the number of cancer patients will reach nearly 19.3 million, which was 14.1 million during 2012. The study also reveals that more than 8.2 million people die from cancer, of which almost 522,000 are women diagnosed with breast cancer. While the mortality rates are higher in the developing regions of the world, the frequency of cancer is higher in developed countries.

The progress of the global market for aurora kinase inhibitors can receive a blow due to the exorbitant costs required in the development of these inhibitors. Small manufacturers might not possess enough capital to invest massively in the creation of advanced aurora kinase inhibitors. Moreover, lack of awareness among the developing economies can also restrict the expansion of the market. However, the adoption of several biological therapies in the domain of oncology will create opportunities for further expansion of the market.

Fill the Form to Gain Deeper Insights on this Market @ http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=4679

Global Aurora Kinase Inhibitors Market: Regional Outlook

By geography, the global market for aurora kinase inhibitors can be segmented into Latin America, Middle East and Africa, Europe, Asia Pacific, and North America. The countries in North America witnessed greater growth when compared with other regions. As a result, North America accounted for the greatest portion of the global revenue. The continuous upgrading of the healthcare sector has been propelling the market for aurora kinase inhibitors in North America.

High growth rate of geriatric population and heightening incidence of cancer rates in Asia Pacific have been responsible for the burgeoning demand for aurora kinase inhibitors in the region. India, China, South Korea, Japan, Malaysia, and Indonesia are likely to contribute substantially to the growth of the market for aurora kinase inhibitors in Asia Pacific over the next few years.

About Us

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

Contact us:

Transparency Market Research
90 State Street,
Suite 700,
Albany
NY – 12207
United States
Tel: +1-518-618-1030
USA – Canada Toll Free 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

Global Bioburden Testing Market Research Report 2023

Bioburden is defined as the number in terms of percentage, colony or cell count of bacteria that thrive on a given unsterilized surface. Bioburden testing, also known as microbial limit testing provides quantification of the bacterial cell cultures on a given unsterilized surface. The major application of bioburden testing lies in implant fixation procedures that require testing ofcertain tolerable bioburden limit before implantation in the human body. The standard for bioburden testing in the US is regulated by the US FDA, whereas global standards are maintained by the ISO (International Organization for Standardization). The quantification for the standardization process is done in terms of colony forming unit (CFU). Bioburden testing is essential in limiting the presence of infection causing bacteria in an object that is to be integrated into a human body as an implant. The testing is important to eliminate the presence of bacterial residue and growth in any object present in natural state. In addition it is almost impossible to remove bacterial residue permanently in an object that is liable to be exposed to open air. Hence sterilization process is performed on an implant object or a device post understanding the bioburden limit. This helps to select the appropriate sterilization technique in order to remove the bacterial burden just prior to the medical (Or other related) procedure. Bioburden testing has therefore saved numerous lives.

Obtain Report Details @ http://www.transparencymarketresearch.com/bioburden-testing-market.html

Based on technology, bioburden testing is segmented into microbial filter method, advanced colorimetric method, and plate count method. Among these, microbial filter method is the most commonly used method for bioburden testing procedures. The plate count method is among the oldest methods for bioburden testing, however is not used regularly on a large scale commercial basis due to its time consuming procedure. Advanced colorimetric method is presently the most promising and widely used bioburden testing technology. The congregation of colometer and computational capabilities has enabled advanced colometric methods to deliver quick results of quantifying bioburden.

Based on equipment, bioburden testing market can be segmented into PCR (polymerase chain reaction) instruments, cell counters, and automated microbial identification systems that are software integrated. Application segment for bioburden testing includes healthcare, aerospace (satellite production & development), supercomputer (super- microprocessor manufacturing) designing, and others (raw material, equipment cleaning, food & beverage). The healthcare industry is the largest application area of bioburden testing.

Geographically, the bioburden testing market is primarily concentrated in the North America and Asia Pacific region. The demand for bioburden testing in the Asia Pacific region is expected to grow, and very likely to replace the North America market soon. Australia, Japan, and China form the largest markets in the Asia Pacific region. South Asia and South East Asia on the other hand show great potential in terms of life sciences and raw material applications; although at present a majority of the growing bioburden testing market consists of life science applications. Besides this, a large number of contract manufacturers reside in the Asia Pacific region. On the other hand, European industries continue to remain a strong point in the global bioburden testing market mainly due to the high quality of products services offered, presence of numerous quality manufacturers and their increased reliability. However certain significant restrictions for bioburden testing remains valid in the European and North American region, such as dearth of trained technicians, overwhelming volume of service demand, and high cost of services, to name a few. The bio-burden testing market in the Rest of the World (ROW) region is expected to grow at a steady rate, albeit slower than the major economies of the world.

Fill the Form to Gain Deeper Insights on this Market @ http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=4669

Some of the well known manufacturers/service providers of bioburden testing equipment/service include: Charles River Laboratories International, Inc., Sigma-Aldrich Corporation, SGS S.A., WuXi PharmaTech (Cayman), and Inc., Merck & Co., Inc., Becton, Dickinson and Company, North American Science Associates, Inc., Nelson Laboratories, Pacific Biolabs, and ATS Labs, Inc.

New Report Examines the Global Outlook for Cancer Genome Sequencing Market Analysis to 2023

Some of the major companies operating in cancer genome sequencing market include Illumina, Inc., Beckman Coulter Genomics, SeqWright, BGI Americas Corporation, Pacific Biosciences, Ambry Genetics, and Foundation Medicine.

Over the last few years, the genomic era of cancer studies is developing at a rapid pace fueled by the emergence of next-generation sequencing technology rendering exquisite resolution and sensitivity. Frequent alterations in their gross chromosomal structure by means of amplification, deletion and inversion of their chromosomal structure forms a characteristic feature of cancer genome. These gene alterations or modifications ultimately lead to cancer onset and progression. Additionally, the gene sequencing for cancer has several advantages over traditional approaches which include the ability to perform complete gene sequencing in single test including the detecting copy number alterations, translocations, and exome-wide base substitutions in all related cancer cells. The reduction in the cost associated with whole genome sequencing and overall time required to perform these sequencing has drastically reduced in last couple of years. A study published by TheHuffingtonPost.com, Inc. in 2013 illustrated that five years ago expenses for performing whole genome sequencing were in millions of dollars which currently can be performed solely for few thousand dollars. Numerous technological advancements have significantly contributed in advancing the research studies pertaining to cancer diagnosis and treatment. Despite this the recombinant DNA cloning is still in its infancy and is yet not competent enough in unraveling the full complexity of the human cell.

Obtain Report Details @ http://www.transparencymarketresearch.com/cancer-genome-sequencing-market.html

In June 2014, a new genome sequencing test developed at Memorial Sloan Kettering known as MSK-IMPACT made cancer analysis far more comprehensive and can be used on any type of solid tumor, irrespective of its location in the human body. According to the scientists of Memorial Sloan Kettering, cancer identification and its predisposition can benefit patients, health practitioners and eventually help in reducing the morbidity and mortality with respect to cancer. A study by Johns Hopkins scientists published in April 2015 illustrated that in last few years several hospitals and companies have collaborated to sequence patient’s tumor in an attempt to personalize therapy for cancer treatment. In addition to selecting personalized therapies for patients with cancer, sequencing the normal tissue genome can also increase the overall understanding of cancer, including finding reasons for cancer predisposition due to germline genome changes.

Regulations pertaining to personalized cancer sequencing are primarily governed by the accreditation of the laboratories performing the sequencing services and analysis, and also the usage of FDA approved tests for conducting these tests. Drivers to the cancer genome sequencing encompass comprehensive view of whole genome, ability to majority of mutations, and eliminating the need for having any prior knowledge about the patient history and current disease status. Such potential growth attributors are likely to boost the demand for gene sequencing-based personalized cancer treatment in the near future. High procedural cost and time consuming interpretation of large datasets are among the key restraints to the market. An alternative to the whole genome sequencing is the targeted gene sequencing method that is comparative less costly, with easy results interpretation and high sensitivity for rare clones.

Fill the Form to Gain Deeper Insights on this Market @ http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=4619

Geographically, the market is studied for four regions; North America, Europe, Asia Pacific and Rest of the World. North America market includes the United States and Canada which form the major revenue contributors owing to increasing inclination towards gene therapy-based cancer treatment. The region is followed by Europe which has also initiated several genome-based studies in cancer. An analysis conducted by Genomics England Ltd. in 2014, revealed that the U.K. is set to become the world leader in ground breaking genetic research into cancer and rare diseases post a grant of USD 473.3 million by Prime Minister of U.K. Asia Pacific and Rest of the World are still in nascent stage owing to the need for high initial investment on laboratory set-up and conducting research activity. However the APAC market is expected to grow in the forthcoming years due to availability of skilled and scientific-based manpower, strength in information technology and its growing economy.

Global Outlook for Cell and Tissue Culture Supplies Market by Key Trends and Analysis 2023

Global Cell and Tissue Supplies Market: Geographical and Competitive Dynamics

In terms of geography, the global cell and tissue supplies market is led by North America. The dominance of the region in this sector is attributed to the vast advancements in cell culture tools in the past few years. Additionally, the rising demand for animal component-free media and the increased demand for automated cell culture systems is expected to further boost the demand for cell culture supplies in North America. Europe is also one of the leading consumers of cell and tissue culture supplies owing to the high concentration of pharmaceutical and biotechnology companies and cell culture researchers in the region. However, Asia-Pacific is expected to emerge as the most promising regional market for cell and tissue suppliers in the next few years. The report presents a thorough analytical overview of the competitive landscape of the market with detailed business profiles of leading cell and tissue supplies manufacturers such as Sigma-Aldrich Co. LLC., STEMCELL Technologies, Capitol Scientific, Inc., Biocompare, Wheaton Industries, Inc., and GE Healthcare Ltd., and VWR International, LLC.

Obtain Report Details @ http://www.transparencymarketresearch.com/cell-tissue-culture-supplies-market.html

Global Cell and Tissue Supplies Market: Snapshot

Cell and tissue culture refers to the process of removing cells and tissues from a plant or an animal and subsequently growing them in controlled artificial environment with conducive temperature, nutrition, and humidity conditions. The process of separating the cells or tissues from their natural environment and shifting them to an artificial environment, called cultivation, involves removing the cell/tissues directly and disaggregating by a mechanical or enzymatic procedure or deriving them from an artificially established cell line.

Over the past several decades of continuous developments, cell culture has emerged as one of the key tools used in molecular and cellular biology to study cell physiology, effects of toxins and various drugs on cells, and biochemistry, mutagenesis, and carcinogenesis of cells. Cell and tissue cultures are also used for the large scale production of biological compounds such as therapeutic proteins and vaccines, and for the screening and development of a variety of therapeutic drugs. The advantage of being able to obtain consistent results from the use of a batch of cultured cells continues to encourage the increased usage of cell and tissue culture for such applications.

This report on the global market for cell and tissue supplies presents a detailed overview of the present state of the market and verifiable projections regarding the future growth prospects of the market and its key segments. Market’s deliverables include a variety of products such as bioreactors, petri-dishes, spreaders, culture cylinders, scrapers and lifters, tissue grinders, syringe filters, and serological pipettes, commonly used for undertaking a number of operations associated with cell and tissue cultures.

Fill the Form to Gain Deeper Insights on this Market @ http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=4503

Global Cell and Tissue Supplies Market: Trends and Opportunities

The global market of cell and tissue supplies is chiefly driven due to the rising demand for artificial organs and biopharmaceutical products across the globe. The vast rise in importance of cell culture technologies in the fields of research and development of a vast variety of therapeutics and bimolecular elements is further fueling the global demand for cell and tissue supplies. The key end users of cell and tissue supplies include biotechnology companies, commercial cell culture laboratories, and pharmaceutical companies.

The market is also significantly benefiting from the development of specialty growth media and culture techniques, which ensure specificity and availability of high-end technology for scaling up cultures. However, ethical concerns over the use of animal sources for cell culture is expected to hamper the growth prospects of the market to a certain extent in the next few years.

About Us

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

Contact us:

Transparency Market Research
90 State Street,
Suite 700,
Albany
NY – 12207
United States
Tel: +1-518-618-1030
USA – Canada Toll Free 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/